Ikonisys Announces Full-Year 2022 Financial Results, Provides Update on Latest Developments


  • A year marked by significant strategic investments and the first sale to the first US customer of the Ikoniscope20 solution, which includes newly added reagents in partnership with Empire Genomics, validates Ikonisys’ business model. , paved the way for accelerated business development.

  • Accelerate commercialization and R&D strategies to lay the foundation for sales growth:

    • Appointment of Gabriel Plan as Sales Director for France

    • Installation of Ikoniscope20 at Toma Advanced Biomedical Assay (Busto Arsizio, Virginia, Italy) to serve as reference lab for R&D and marketing

    • Partnership with Evosciences Leasing supports international expansion

    • Concluded an agreement with Politecnico di Milano for research activities in the fields of machine learning and biotechnology

    • Presentation of preliminary results of collaborative research with the University of Connecticut (UConn). We show that the ability of his Ikoniscope20 in detecting rare cells may outperform the current standards of immuno-oncology testing.

    • Partnership with Empire Genomics expands portfolio of optimized probes to meet the high-performance testing needs of Ikoniscope20 customers.

    • Entered into a distribution partnership with BioVendor Laboratory Medicine to distribute the Ikoniscope20 system in Eastern Europe

    • Installation of the Ikoniscope20 solution at a U.S. urological laboratory that is part of a major national healthcare delivery group

    • Launched the Ikoniscope20max measuring instrument for large customers.

    • Establishment of cooperation with Integrated Gulf Biosystems Group to market the Ikoniscope20 system in the Middle East market (subsequent event, after December 30, 2022)

Paris, April 29, 2023–(BUSINESS WIRE)–Regulatory News:

Ikonisys SA (Code ISIN: FR00140048X2 / Ticker: ALIKO), a company specializing in the early and accurate detection of cancer using unique, fully automated solutions for medical diagnostic laboratories, announced today 12 December 2022 announced the results of its annual audit for the year ending March 31. Approved by the Board of Directors on April 28, 2023 to provide an update on the latest developments.

Ikonisys CEO Mario Crovetto said:Said: “2022 is another very important year for us. Earlier this year, we started commercializing Ikoniscope20, a fully automated solution for molecular diagnostics. It is used especially in pathology laboratories for oncological FISH tests. In December, we announced the launch of the Ikoniscope20max. This is his version of the Ikoniscope, especially suited for high-volume labs. In addition to advancing the implementation of our commercial strategy, we further strengthened our technology platform through a targeted research and development program. In particular, he is working on his field of CTCs, which holds great promise in early cancer detection and treatment monitoring. In addition, we will continue to update and expand our application portfolio and integrate artificial intelligence into our platform. So from 2022 to his early 2023, Ikonisys has consistently moved forward along the path he outlined during his IPO in July 2021, effectively laying the groundwork for sales growth. “

Full Year 2022 Results vs. 2021 – Audited Simplified Consolidated Income Statement




net sales



Other income/income



Cost of sales



operating expenses



Operating Income/(Loss)



Finance income / (loss)





Net Profit / (Loss)



Cash and cash equivalents at end of period



Details of major changes in the financial statements

Net sales for the period ended December 31, 2022 were €617,000 compared to €365,000 for the period ended December 31, 2021, a 69% increase thanks to the initial sales of the Ikoniscope20, especially in the United States. has increased significantly.

The increase in operating expenses is primarily related to R&D projects and sales and marketing related to Ikoniscope20. As for R&D expenses, until last year they were capitalized, but from 2022 they will be depreciated in parallel with the income started to be generated by a particular R&D project. As far as sales and marketing expenses are concerned, the increase is primarily due to the hiring of new employees and the launch of marketing activities.

Taking into account the above factors, the operating result for 2021 is €2.7 million versus €0.4 million for 2021.

The consolidated cash position as of December 31, 2022 is EUR 94,000, compared to EUR 1.5 million as of December 31, 2021. With Atlas Capital Markets on October 5, 2022.

Strategy and outlook

Ikonisys plans to leverage marketing efforts launched in 2022 to accelerate its commercialization strategy. The company continues its direct sales and marketing activities with renewed prospects in the US and major his EU countries. Additionally, we are actively working to establish additional distribution agreements to add to our existing portfolio of partners to expand our global reach for future customers.

In addition, Ikonisys will leverage its strong network of development partners to serve new market segments such as circulating tumor cells (CTC) and immuno-oncology. These authoritative partners include Sheba Medical Center in Tel Aviv, Tomalab in Milan (circulating tumor cells) and University of Connecticut (immuno-oncology).

Finally, the company continues to focus on technological innovation, especially the use of artificial intelligence (AI) in medical diagnostics. In particular, the company is advancing deep learning-based image analysis to complete the next generation of his Ikoniscope solution, his Ikoniscope AI for personalized medicine.

About Iconisis

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy), specializing in the early and accurate detection of cancer. The company develops, manufactures and sells its own Ikoniscope20.® This platform is a fully automated solution designed to provide accurate and reliable detection and analysis of rare and very rare cells. Ikonisys is FDA cleared for multiple automated diagnostic applications, which are also CE certified and marketed in Europe. Through its breakthrough fluorescence microscopy platform, the company continues to develop a range of new tests, including liquid biopsy tests based on circulating tumor cells (CTCs).

For more information, please visit www.Ikonisys.com.


This press release contains forward-looking statements regarding our prospects and developments. These statements use future tenses, conditional tenses, and positive They may be identified by their use of words. “, “could”, “would”, “will” or, where applicable, the negative of these terms, or other similar variations or expressions. This information is based on data, assumptions and estimates we believe to be reasonable and is subject to change or change due to uncertainties regarding the economic, financial, competitive and regulatory environment. This information includes data regarding, among other things, our intentions, estimates and targets with respect to our markets, strategies, growth, results, financial condition and cash flow. The forward-looking information contained in this press release speaks only as of the date of this press release.We will not update any forward-looking information contained in this press release except as required by applicable law or regulation. We operate in a competitive and rapidly changing environment and are subject to all risks, uncertainties or other factors that may affect our business. We cannot predict the potential impact on or the extent to which any one risk or combination of risks may materialize.Please note that these forward-looking information are not guarantees of actual results. please.

View source version at businesswire.com: https://www.businesswire.com/news/home/20230429005029/en/

contact address

Alessandro Mauri

new cap
Olivier Bricot / Louis-Victor Derouvelier
PR for investors
Phone: +33 (0)1 44 71 94 92

new cap
Nicolas Merigoud
Media contact point
Phone: +33 (0)1 44 71 94 98

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *